The total return for Cencora, Inc. (COR) stock is -3.81% over the past 12 months vs. +24.28% for the S&P 500. So far it's up -16.27% this year. Includes price appreciation + reinvested dividends.
Cencora, Inc. (COR) Compound Annual Growth Rates (CAGR) Summary
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (4.53%) | +16.24% | +18.63% | +13.92% | +13.68% | +13.97% |
| Total Return CAGR | (3.81%) | +17.24% | +19.86% | +17.22% | +16.59% | +16.41% |
| Revenue CAGR | +5.95% | +9.91% | +10.86% | +8.75% | +9.97% | +9.10% |
| Net Income CAGR | +50.51% | +16.38% | +8.79% | +5.35% | +9.21% | +9.75% |
| EPS CAGR | +5.53% | (0.53%) | +11.97% | +18.67% | +8.81% | +12.58% |
| Free Cash Flow CAGR | (56.42%) | (13.97%) | +3.95% | (8.05%) | +2.05% | +2.81% |
| Operating Cash Flow CAGR | (44.63%) | (7.89%) | +6.51% | (5.27%) | +3.60% | +4.01% |
| Dividends CAGR | +8.18% | +6.45% | +5.77% | (2.84%) | +13.43% | +23.84% |
CAGR Trends History
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
COR Total Return CAGR Chart
Cencora, Inc. (COR)
Annual Total Returns Comparison
| Year | Start Value | End Value | COR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | 12698.13 | 10632.04 | (16.27%) | +9.08% | (25.35%) |
| 2025 | 8382.41 | 12698.13 | +51.49% | +17.72% | +33.77% |
| 2024 | 7594.36 | 8382.41 | +10.38% | +24.89% | (14.51%) |
| 2023 | 6059.74 | 7594.36 | +25.32% | +26.19% | (0.87%) |
| 2022 | 4799.41 | 6059.74 | +26.26% | (18.17%) | +44.43% |
| 2021 | 3477.04 | 4799.41 | +38.03% | +28.74% | +9.29% |
| 2020 | 2971.69 | 3477.04 | +17.01% | +18.37% | (1.36%) |
| 2019 | 2409.00 | 2971.69 | +23.36% | +31.22% | (7.86%) |
| 2018 | 2781.91 | 2409.00 | (13.40%) | (4.56%) | (8.84%) |
| 2017 | 2236.87 | 2781.91 | +24.37% | +21.70% | +2.67% |
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch